Immunotherapy for primary immunodeficiency diseases.
The 2 most commonly encountered primary immunodeficiency syndromes in adult practice are antibody deficiency disorders and hereditary angioedema.Immunologic therapy for these disorders has significantly improved patient management. Therapy with immunoglobulin leads to improvement in overall quality of life. With increasing survival rates and decreasing levels of life-threatening infections in patients with primary antibody deficiencies, disease complications are more commonly encountered. Treatment of these complications with monoclonal antibody therapy seems promising and is likely to increase in the future. More recently,several additional agents have become available, including novel drugs targeted at different elements of the disease process.
Department of Clinical Immunology, St James's University Hospital, Beckett Wing, Leeds, Yorkshire LS9 7TF, UK. philipwood1@nhs.net
Philip
P
Wood
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000744:Anemia, Hemolytic, Autoimmune / Q000628:therapy; D054179:Angioedemas, Hereditary / Q000628:therapy; D001920:Bradykinin / Q000031:analogs & derivatives / Q000627:therapeutic use; D003174:Complement C1 Inactivator Proteins / Q000627:therapeutic use; D050718:Complement C1 Inhibitor Protein / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D057210:Delayed Diagnosis; D018562:Disease Transmission, Infectious; D005374:Filtration / Q000379:methods; D006099:Granuloma / Q000628:therapy; D018718:Home Infusion Therapy; D006801:Humans; D006968:Hypersensitivity, Delayed; D006969:Hypersensitivity, Immediate; D007116:Immunization, Passive; D007074:Immunoglobulin G / Q000097:blood; D007136:Immunoglobulins / Q000627:therapeutic use*; D007153:Immunologic Deficiency Syndromes / Q000628:therapy*; D007239:Infections / Q000453:epidemiology; D007610:Kallikreins / Q000037:antagonists & inhibitors; D036103:Nanotechnology; D010455:Peptides / Q000627:therapeutic use; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000628:therapy; D011786:Quality Control; D011788:Quality of Life; D011994:Recombinant Proteins / Q000627:therapeutic use; D012646:Self Administration; D013678:Technology, Pharmaceutical
D000319:Adrenergic beta-Antagonists; D003174:Complement C1 Inactivator Proteins; D050718:Complement C1 Inhibitor Protein; D007074:Immunoglobulin G; D007136:Immunoglobulins; D010455:Peptides; D011994:Recombinant Proteins; C511194:ecallantide; C571093:conestat alfa; C065679:icatibant; D007610:Kallikreins; D001920:Bradykinin